The Priority Review

The stream · Daily digest

The stream: Wednesday, November 4, 2026

15 briefs from ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 10

  1. Innovent registers Phase III trial of sintilimab with LCCRT in locally advanced rectal cancer

    The study, led by Innovent Biologics (Suzhou) Co. Ltd., plans to enroll 500 participants with locally advanced rectal cancer and is planned to start on November 25, 2026. It evaluates sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy versus the same regimen without sintilimab.

    Source: ClinicalTrials.gov registry record, November 4, 2026

  2. Boehringer Ingelheim registers Phase 3 study of verducatib in bronchiectasis

    The study, NCT07915219, plans to enroll 1500 participants and begin on January 11, 2027, to evaluate long-term safety and efficacy of verducatib in patients with bronchiectasis. Participants can stay in the study for up to 1 year and 9 months, with primary completion projected for July 31, 2029.

    Source: ClinicalTrials.gov registry record, November 4, 2026

  3. Colgate Palmolive registers Phase 3 trial of stannous fluoride vs regular fluoride toothpaste

    The study was first posted on ClinicalTrials.gov on November 4, 2026 and currently has 84 participants enrolled. It is planned to complete primary outcomes in April 2027.

    Source: ClinicalTrials.gov registry record, November 4, 2026

  4. Ascendis registers Phase 3 trial of navepegritide in hypochondroplasia

    The study, led by Ascendis Pharma A/S, plans to enroll 81 children and adolescents with hypochondroplasia and has a planned start date of November 2026. It is a randomized, double-blind, placebo-controlled trial that plans to reach primary completion in October 2028.

    Source: ClinicalTrials.gov registry record, November 4, 2026

  5. Novartis posts results of Phase 3 KLU156 trial in uncomplicated P. Falciparum malaria

    The study, led by Novartis Pharmaceuticals, enrolled 1720 participants and completed enrollment on March 7, 2024, with primary completion on June 27, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026, confirming the efficacy, safety and tolerability of KLU156 compared with Coartem in adults and children.

    Source: ClinicalTrials.gov results record, November 4, 2026

  6. Takeda posts results of Phase 3 TAK-279 study in psoriasis

    The study enrolled 18 participants and completed primary data collection on October 17, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.

    Source: ClinicalTrials.gov results record, November 4, 2026

  7. Alexion posts results of Phase 3 ravulizumab trial in HSCT-TMA

    The study enrolled 148 participants and completed primary data collection on September 19, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.

    Source: ClinicalTrials.gov results record, November 4, 2026

  8. Novo Nordisk posts results of Phase 3 KBP-5074 trial in uncontrolled hypertension and CKD

    The study enrolled 666 participants and began on November 5, 2021, with primary completion on January 30, 2024. The trial was terminated and the results were first posted on ClinicalTrials.gov on November 4, 2026.

    Source: ClinicalTrials.gov results record, November 4, 2026

  9. Cognixion enrolls participants in NIH-funded BCI study for ALS

    Cognixion Corporation announced it is now enrolling 30 adults with ALS in the CHOICE study, a 12-week trial comparing its investigational brain-computer interface with eye-tracking devices. The study is supported by the National Institute on Deafness and Other Communication Disorders and is registered on ClinicalTrials.gov as NCT07871071.

    Source: Company press release (PR Newswire), November 4, 2026

  10. Minghui and ASKA enter exclusive license for MHB018A in Japan

    Minghui Pharmaceutical and ASKA Pharmaceutical announced an exclusive license agreement for the development and commercialization of MHB018A in Japan, with ASKA receiving rights to seek regulatory approval and commercialize the antibody. The agreement includes an upfront payment of USD 110 million and potential milestone payments of up to USD 330 million, plus tiered royalties up to mid-30 % on net sales in Japan.

    Source: Company press release (PR Newswire), November 4, 2026

Policy · 3

  1. CMS finalizes 2027 Home Health payment rule, adds enrollment revocation changes

    On November 4, 2026, the Centers for Medicare & Medicaid Services issued a final rule that updates the Home Health Prospective Payment System for CY 2027, including a 2.1% payment increase ($365 million) and a 0.3% fixed-dollar-loss adjustment ($50 million). The rule also makes all revocation grounds retroactive.

    Source: CMS fact sheet, November 4, 2026

  2. Sanofi tops 2026 CNS Summit Digital Innovation Index

    The index ranks the top 30 pharmaceutical companies on digital innovation, using publicly reported initiatives and investments from July 2025 through July 2026. The top 10 list includes Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA.

    Source: Company press release (PR Newswire), November 4, 2026

  3. WuXi Biologics receives double honors at 2026 HERA for ESG reporting and environmental excellence

    WuXi Biologics (2269.HK) won Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact at the ninth Hong Kong ESG Reporting Awards, becoming the only pharmaceutical company to receive a Grand Award. The company said the awards recognize its ongoing commitment to transparent ESG disclosure and measurable environmental progress across its global operations.

    Source: Company press release (PR Newswire), November 3, 2026

Regulation · 2

  1. CMS finalizes CY 2027 Medicare Physician Fee Schedule rule

    The Centers for Medicare & Medicaid Services published a final rule on November 4, 2026 that finalizes policy changes for Medicare payments under the Physician Fee Schedule effective Jan. 1, 2027. The rule includes a +0.75% conversion factor for qualifying APM participants and a +0.25% factor for non-qualifying participants, with overall payment reductions of 1.83% and 2.31% respectively compared to CY 2026.

    Source: CMS fact sheet, November 4, 2026

  2. CMS finalizes broad Medicare integrity changes in home health final rule

    CMS finalized a CY 2027 Home Health Prospective Payment System final rule that is expected to save taxpayers approximately $82 million annually by strengthening its ability to recover Medicare payments from noncompliant providers and suppliers. The rule also shortens the OASIS data submission deadline from 135 days to 45 days, potentially reducing the public reporting lag by up to three months.

    Source: CMS press release, November 4, 2026